Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy

Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy

Targeted therapy is an efficient treatment for patients with epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Therapeutic resistance invariably occurs in NSCLC patients. Many studies have focused on drug resistance mechanisms, but only a few have addressed the...

Full description

Bibliographic Details
Main Authors: Chung-Yu Huang, Li-Han Hsu, Chung-Yeh Chen, Gee-Chen Chang, Hui-Wen Chang, Yi-Mei Hung, Ko-Jiunn Liu, Shu-Huei Kao
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cancers
Subjects:
nsclc
gefitinib-resistant
egfr
alternative metabolism
monocarboxylate transporter 1
Online Access:https://www.mdpi.com/2072-6694/12/1/181

Internet

https://www.mdpi.com/2072-6694/12/1/181

Similar Items